The identification of the FGFR3-TACC3 fusion in various cancers, through state-of-the-art diagnostic methods such as RNA sequencing, reverse transcription polymerase chain reaction, and immunostaining, underscores its significance in the field of targeted cancer therapy. This evidence concerns the gene TACC3 and cancer.